A number of analysts tracking Healthways have reacted positively to the company's Q2 profits. At Stifel Nicolaus, Thomas Carroll has hiked his price target for the Franklin-based company, which he rates a 'buy,' to $13 from $10. Michael Petusky at Noble Financial has upgraded Healthways (Ticker: HWAY) to 'buy' from 'hold' and given it a $12 target.

Not so enthused is Art Henderson at Jefferies, who has downgraded shares of AmSurg to 'hold' after the surgery center chain's Q2 numbers. Nashville-based Henderson says he has "serious concerns" about AmSurg's valuation given various macroeconomic uncertainties. His new $27 target is about 10 percent below where AmSurg (Ticker: AMSG) is changing hands this morning.